This site is intended for healthcare professionals

Sign in
Go to /sign-in page

You can view 5 more pages without signing in

NICE guidance - Carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

Summary points from the guidance (1):

  • temozolomide, within its licensed indications, is recommended as an option for the treatment of newly diagnosed glioblastoma multiforme in patients with a World Health Organization (WHO) performance status of 0 or 1
  • carmustine implants, within their licensed indications, are recommended as an option for the treatment of newly diagnosed high-grade glioma only for patients in whom 90% or more of the tumour has been resected
  • treatment with carmustine implants should be provided only within specialist centres

Notes:

  • WHO performance status classification categorises patients as:
    • 0: able to carry out all normal activity without restriction
    • 1: restricted in strenuous activity but ambulatory and able to carry out light work
    • 2: ambulatory and capable of all self-care but unable to carry out any work activities; up and about more than 50% of waking hours
    • 3: symptomatic and in a chair or in bed for greater than 50% of the day but not bedridden
    • 4: completely disabled; cannot carry out any self-care; totally confined to bed or chair

Reference:

  1. NICE (June 2007). Carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma.

Related pages

Create an account to add page annotations

Create a free account

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.